Adult human sarcomas. I. Basic science

References

• Hoshi H, Matsumoto S, Manabe J et al. Malignant change secondary to fibrous dysplasia. Int. J. Clin. Oncol.11(3), 229–235 (2006).
   PubMedGoogle Scholar
• Ceulemans J, De Wever I, Sciot R et al. A sarcoma at the site of previous extravasation of adriamycin. Sarcoma6(4), 135–139 (2002).
   PubMedGoogle Scholar
• Hoogduijn MJ, Rakonczay Z, Genever PG. The effects of anticholinergic insecticides on human mesenchymal stem cells. Toxicol. Sci. (2006) (Epub ahead of print).
   PubMedGoogle Scholar
• Shibuya M, Hanafusa T, Hanafusa H, Stephenson JR. Homology exists among the transforming sequences of avian and feline sarcoma viruses. Proc. Natl. Acad. Sci. USA77(11), 6536–6540 (1980).
   PubMed Web of Science ®Google Scholar
• Neil JC, Delamarter JF, Vogt PK. Evidence for three classes of avian sarcoma viruses: comparison of the transformation-specific proteins of PRCII, Y73 and Fujinami viruses. Proc. Natl. Acad. Sci. USA78(3), 1906–1910 (1981).
   PubMedGoogle Scholar
• Groffen J, Heisterkamp N, Shibuya M et al. Transforming genes of avian (v-fps) and mammalian (v-fes) retroviruses correspond to a common cellular locus. Virology125(2), 480–486 (1983).
   PubMedGoogle Scholar
• Hammond CI, Vogt PK, Bishop JM. Molecular cloning of the PRCII sarcoma viral genome and the chicken proto-oncogene c-fps. Virology143(1), 300–308 (1985).
   PubMedGoogle Scholar
• Neckameyer WS, Shibuya M, Hsu MT, Wang LH. Proto-oncogene c-ros codes for a molecule with structural features common to those of growth factor receptors and displays tissue specific and developmentally regulated expression. Mol. Cell Biol.6(5), 1478–1486 (1986).
   PubMedGoogle Scholar
• Su HY, Bos TJ, Monteclaro FS, Vogt PK. Jun inhibits myogenic differentiation. Oncogene6(10), 1759–1766 (1991).
   PubMedGoogle Scholar
• Fukui Y, Saltiel AR, Hanafusa H. Phosphatidylinositol-3 kinase is activated in v-src, v-yes and v-fps transformed chicken embryo fibroblasts. Oncogene6(3), 407–411 (1991).
   PubMedGoogle Scholar
• Zong CS, Poon B, Chen J, Wang LH. Molecular and biochemical bases for activation of the transforming potential of the proto-oncogene c-ros. J. Virol.67(11), 6453–6462 (1993).
   PubMedGoogle Scholar
• Shimizu K, Ichikawa H, Tojo A et al. An ets-relateted gene, ERG, is rearranged in human myeloid leukemia with t(16;21) chromosomal translocation. Proc. Natl. Acad. Sci. USA90(21), 10280–10284 (1993).
   PubMed Web of Science ®Google Scholar
• Sing DC, McMullan DJ, Roberts P et al. FUS/ERG gene fusions in Ewing’s tumors. Cancer Res.63(15), 4568–4576 (2003).
   PubMedGoogle Scholar
• Jia R, Hanafusa H. The proto-oncogene of v-eyk (v-ryk) is a novel receptor-type protein tyrosine kinase with extracellular Ig/GN-III domains. J. Biol. Chem.269(3), 1839–1844 (1994).
   PubMed Web of Science ®Google Scholar
• Chang HW, Li J, Kretzschmar D, Vogt PK. Avian cellular homolog of the qin oncogene. Proc. Natl. Acad. Sci. USA92(2), 447–451 (1995).
   PubMedGoogle Scholar
• Huai L, Chiocca SM, Gilbreth MA, Ainsworth JR, Bishop LA, Murphy EC Jr. Moloney sarcoma virus MuSVts110 DNA: cloning, nucleotide sequence and gene expression. J. Virol.66(9), 5329–5337 (1992).
   PubMedGoogle Scholar
• Jiang D, Flyer DC. Immune response to Moloney murine leukemia virus nonviral, tumor-associated antigens fail to provide in vivo tumor protection. J. Immunol.148(3), 974–980 (1992).
   PubMedGoogle Scholar
• Milde-Langosch K. The Fos family of transcription factors and their role in tumorigenesis. Eur. J. Cancer41(16), 2449–2461 (2005).
   PubMed Web of Science ®Google Scholar
• Tanaka KK, Yoshida TO, Tanaka T, Kojima K, Hanaichi T. Different neoplastic response of mice and rats to infection by murine sarcoma virus (Moloney). Gann.63(4), 445–457 (1972).
   PubMedGoogle Scholar
• Feig LA. The odyssey of K-ras. Mol. Cell.21(4), 447–449 (2006).
   PubMedGoogle Scholar
• Besmer P, Murphy JE, George PC et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature320(6061), 415–421 (1986).
   PubMed Web of Science ®Google Scholar
• Majumder S, Ray, P, Besmer P. Tyrosine protein kinase activity of the HZ4-feline sarcoma virus P80gag-kit-transforming protein. Oncogene Res.5(4), 329–335 (1990).
   PubMedGoogle Scholar
• Johnsson A, Heldin CH, Wasteson A et al. The c-sis gene encodes a precursor of the B chain of platelet-derived growth factor. EMBO J.3(5), 921–928 (1984).
   PubMed Web of Science ®Google Scholar
• Pierce GF, Shawver LK, Milner PG et al. Identification and purification of PDGF/sis-like proteins from nuclei of simian sarcoma virus-transformed fibroblasts. Oncogene Res.2(3), 235–244 (1988).
   PubMedGoogle Scholar
• Sinkovics JG, Györkey F, Kusyk C, Siciliano MJ. Growth of human tumor cells in established cultures. In: Methods in Cancer Research. Busch H (Ed.). Academic Press, New York, San Francisco, London, vol. XIV, 243–323 (1978).
   Google Scholar
• Sinkovics JG, Shirato E, Gyorkey F et al. Relationship between lymphoid neoplasms and immunologic functions. In: Leukemia-Lymphoma. Year Book Medical Publishers, Inc., Chicago, USA 53–92 (1970).
   Google Scholar
• Sinkovics JG, Plager C, McMurtrey MJ et al. Immunotherapy of human sarcomas. In: Management of Primary Bone & Soft Tissue Tumors. Year Book Medical Publishers, Inc., Chicago, USA 361–410 (1977).
   Google Scholar
• Giraldo G, Beth E, Hirshaut Y et al. Human sarcomas in culture. Foci of altered cells and a common antigen; induction of foci and antigen in human fibroblast cultures by filtrates. J. Exp. Med.133(3), 454–478 (1971).
   PubMed Web of Science ®Google Scholar
• Morton DL, Hall WT, Malmgren RA. Human liposarcomas: tissue cultures containing foci of transformed cells with viral particles. Science165, 813–815 (1969).
   PubMedGoogle Scholar
• Sinkovics JG, Horvath JC. Kaposi’s sarcoma: breeding ground of Herpesviridae. Internat. J. Oncol.14(4), 615–646 (1999). Erratum 27(1), 33 (2005).
   PubMedGoogle Scholar
• Akula SM, Ford PW, Whitman AG et al. B-Raf-dependent expression of vascular endothelial growth factor-A in Kaposi sarcoma-associated herpesvirus-infected human B cells. Blood105(11), 4516–4522 (2005).
   PubMed Web of Science ®Google Scholar
• Masood R, Xia G, Smith P et al. Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium. Blood105(3), 1310–1318 (2005).
   PubMed Web of Science ®Google Scholar
• Ford PW, Bryan BA, Dyson OF, Weidner DA, Chintagattu V, Akula SM. Raf/MEK/ERK signaling triggers reactivation of Kaposi’s sarcoma-associated herpesvirus latency. J. Gen. Virol.87(5), 1139–1144 (2006).
   PubMed Web of Science ®Google Scholar
• Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-κB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood96(7), 2537–2542 (2000).
   PubMed Web of Science ®Google Scholar
• Fiorelli V, Gendelman R, Sirianni MC et al. γ interferon produced by CD8+ T cells infiltrating Kaposi’s sarcoma induces spindle cells with human immunodeficiency virus-1 Tat protein: an immune response to human herpesvirus-8 infection? Blood91(3), 956–967 (1998).
   PubMed Web of Science ®Google Scholar
• Humer J, Waltenberger A, Grassauer A et al. Identification of a melanoma marker derived from melanoma-associated endogenous retroviruses. Cancer Res.66(3), 1658–1663 (2006).
   PubMed Web of Science ®Google Scholar
• Hirschl S, Schanab O, Seppele H et al. Sequence variability of retroviral particles derived from human melanoma cells: melanoma-associated retrovirus. Virus Res. (2006) (Submitted).
   PubMedGoogle Scholar
• Strick R, Ackermann S, Langbein M et al. Proliferation and cell-cell fusion of endometrial carcinoma are induced by the human endogenous retroviral syncytin-1 and regulated by TGF-β. J. Mol. Med. (2006) (Submitted).
   PubMedGoogle Scholar
• Wang-Johanning F, Liu J, Rycaj K et al. Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int. J. Cancer120(1), 81–90 (2007).
   PubMed Web of Science ®Google Scholar
• Wang Y, Jiang JD, Xu D et al. A mouse mammary virus-like long terminal repeat superantigen in human breast cancer. Cancer Res.64(12), 4105–4111 (2004).
   PubMed Web of Science ®Google Scholar
• Urisman A, Molinaro RJ, Fischer N et al. Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLos Pathog.2(3), (2006).
   PubMedGoogle Scholar
• Carroll KD, Bu W, Palmeri D et al. Kaposi’s sarcoma-associated herpesvirus lytic switch protein stimulates DNA binding of RBP-Jk/CSL to activate the Notch pathway. J. Virol.80(19), 9697–9709 (2006).
   PubMedGoogle Scholar
• Verma SC, Lan K, Choudhuri T, Robertson ES. Kaposi’s sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen modulates K1 expression through its cis-acting elements within the terminal repeats. J. Virol.80(7) (2006).
   Google Scholar
• Sharma-Walia N, Raghu H, Sadagopan S et al. Cyclooxygenase 2 induced by Kaposi’s sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression. J. Virol.80(13), 6534–6552 (2006).
   PubMedGoogle Scholar
• Sodhi A, Chaisuparat R, Hu J et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell10(2), 133–143 (2006).
   PubMed Web of Science ®Google Scholar
• Chang H. Notch signal transduction induces a novel profile of Kaposi’s sarcoma-associated herpesvirus gene expression. J. Microbiol.44(2), 217–225 (2006).
   PubMedGoogle Scholar
• Wang L, Dittmer DP, Tomlinson CC et al. Immortalization of primary endothelial cells by the K1 protein of Kaposi’s sarcoma-associated herpesvirus. Cancer Res.66(7), 3658–3666 (2006).
   PubMed Web of Science ®Google Scholar
• Grossmann C, Podgrabinska S, Skobe M, Ganem D. Activation of NF-kappaB by the latent vFLIP gene of Kaposi’s sarcoma-associated herpesvirus is required for the spindle shape of virus-infected endothelial cells and contributes to their proinflammatory phenotype. J. Virol.80(14), 7179–7185 (2006).
   PubMed Web of Science ®Google Scholar
• Fuld S, Cunningham C, Klucher K et al. Inhibition of interferon signaling by the Kaposi’s sarcoma-associated herpesvirus full-length viral interferon regulatory factor 2 protein. J. Virol.80(6) 3092–3097 (2006).
   PubMedGoogle Scholar
• Little RF, Yarchoan R. Poor specific T cell response to human herpesvirus 8: a key to unleashing Kaposi sarcoma? J. Infect. Dis.194(8), 1030–1031 (2006).
   PubMedGoogle Scholar
• Reeaee SA, Cunningham C, Davidson AJ, Blackbourn DJ. Kaposi’s sarcoma-associated herpesvirus immune modulation: an overview. J. Gen. Virol.87(7), 1781–1804 (2006).
   PubMedGoogle Scholar
• Pantanowitz L, Schwartz EJ, Dezube BJ et al. c-Kit (CD117) expression in AIDS-related, classic and African endemic Kaposi sarcoma. Appl. Immunohistochem. Mol. Morphol.13(2), 162–166 (2005).
   PubMedGoogle Scholar
• Cohen CD, Horster S, Sander CA, Bogner JR. Kaposi’s sarcoma associated with tumour necrosis factor α neutralizing antibody. Ann. Rheum. Dis.62(7), 684 (2003).
   PubMed Web of Science ®Google Scholar
• Zmonarski SC, Boratynska M, Rabczynski J et al. Regression of Kaposi’s sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplat. Proc.37(2) 964–966 (2005).
   PubMedGoogle Scholar
• Connick E, Kane MA, White IE et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin. Infect. Dis.39(12), 1852–1855 (2004).
   PubMed Web of Science ®Google Scholar
• Crane HM, Deubner H, Huang JC et al. Fatal Kaposi’s sarcoma-associated immune reconstitution following HAART initiation. Int. J. STD. AIDS16(1), 80–83 (2005).
   PubMedGoogle Scholar
• Leidner RS, Aboulafia DM. Recrudescent Kaposi’s sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS19(10), 635–644 (2005).
   PubMed Web of Science ®Google Scholar
• Bower M, Nelson M, Young AM et al. Immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma. J. Clin. Oncol.23(22), 5224–5228 (2005).
   PubMed Web of Science ®Google Scholar
• Khakoo AY, Pat S anderson SA et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J. Exp. Med.203(5), 1235–1247 (2006).
   PubMed Web of Science ®Google Scholar
• Taubert H, Greither T, Kaushal D et al. Expression of the stem cell self-renewal gene Hiwi and risk of tumour-related death in patients with soft tissue sarcoma. Oncogene (2006) (Epub ahead of print).
   PubMedGoogle Scholar
• Matushansky I, Hernando E, Singer S et al. β-catenin loss-of-function and its putative role as a tumor suppressor in sarcomagenesis. Proceedings 97th Annual Meeting, American Association of Cancer Research. Washington, DC. USA. 47, 1082–4609 (2006) (Abstract 4609).
   Google Scholar
• Matushansky I, Socci N, Hernando E et al. A putative tumor suppressor role for Wnt-signaling in sarcomagenesis.Proceedings 42nd Annual Meeting American Society of Clinical Oncology. Atlanta, GA, USA. Supplement J. Clin. Oncol.24(18) Part I, 521 (2006) (Abstract 9507).
   Google Scholar
• Riggi N, Cironi L, Provero P et al. Development of Ewing’s sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res.65(24), 11459–11468 (2005).
   PubMed Web of Science ®Google Scholar
• Uren A, Toretsky JA. Ewing’s sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent. Future Oncol.1(4) 521–528 (2005).
   PubMedGoogle Scholar
• Coffman JA. Runx transcription factors and the developmental balance between cell proliferation and differentiation. Cell Biol. Int.27(4), 315–324 (2003).
   PubMed Web of Science ®Google Scholar
• Szalasznyk RM, Klees RF, Boskey A, Plopper GE. Activation of FAK is necessary for the osteogenic differentiation of human mesenchymal stem cells on laminin. J. Cell Biochem. (2006) (Epub ahead of print).
   Google Scholar
• Gibbs CP, Kukekov VG, Reith JD et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia7(11), 967–976 (2005).
   PubMed Web of Science ®Google Scholar
• Sorensen KD, Quintanilla-Martinez L, Kunder S et al. Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3–3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors evolution toward induction of other disease patterns. J. Virol.78(23) 13216–13231 (2006).
   Google Scholar
• Yagi MJ, Holland JF, Bekesi JG. Tumor necrosis factor enhances murine SL3–3 retrovirus replication. J. Clin. Lab. Immunol.24(3), 129–134 (1987).
   PubMedGoogle Scholar
• Blyth K, Vaillant F, Hanlon L et al. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res.66(4), 2195–2201 (2006).
   PubMed Web of Science ®Google Scholar
• Blyth K, Cameron ER, Neil JC. The Runx genes: gain or loss of function in cancer. Nature Rev. Cancer5(5), 376–387 (2005).
   PubMed Web of Science ®Google Scholar
• Yoshida CA, Komori T. Role of Runx proteins in chondrogenesis. Crit. Rev. Eukaryot. Gene Expr.15(3) 243–254 (2005).
   PubMedGoogle Scholar
• Edgar AJ, Dover SL, Lodrick MN et al. Bone morphogenetic protein-2 induces expression of murine zinc finger transcription factor ZNF450. J. Cell Biochem.94(1), 202–215 (2005).
   PubMedGoogle Scholar
• Valta MP, Hentunen T, Qu Q et al. Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8. Endocrinology147(5), 2171–2182 (2006).
   PubMedGoogle Scholar
• Chandar N, Swindle J, Szajkovics A, Kolman K. Relationship of bone morphogenetic protein expression during osteoblast differentiation to wild type p53. J. Orthop. Res.23(6), 1345–1353 (2005).
   PubMed Web of Science ®Google Scholar
• Patane S, Avnet S, Coltella N et al. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res.66(9), 4750–4757 (2006).
   PubMed Web of Science ®Google Scholar
• Nishijo K, Nakayama T, Aoyama T et al. Mutation analysis of the RECQL4 gene in sporadic osteosarcomas. Int. J. Cancer111(3), 3670–372 (2004).
   Google Scholar
• Wang LL, Gannavarapu A, Kozinetz CA et al. Association between osteosarcoma and deleterious mutations in the RECQKL4 gene in Rothmund-Thomson syndrome. J. Natl Cancer Inst.95(9), 669–674 (2003).
   PubMed Web of Science ®Google Scholar
• Werner SR, Prahalad AK, Yang J, Hock JM. RECQL4-deficient cells are hypersensitive to oxidative stress/damage: insights for osteosarcoma prevalence and heterogeneity in Rothmund-Thomson syndrome. Biochem. Biophys. Res. Commun.345(1), 403–409 (2006).
   PubMedGoogle Scholar
• Ajuh P, Kuster B, Panov K et al. Functional analysis of the human CDC5L complex and identification of its components by mass spectrometry. EMBO J.19(23), 6569–6581 (2000).
   PubMed Web of Science ®Google Scholar
• Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: lipoma. Cancer Genet. Cytogenet.150(2), 93–115 (2004).
   PubMedGoogle Scholar
• Sandberg AA. Update on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet. Cytogenet.155(1), 1–24 (2004).
   PubMedGoogle Scholar
• Antonescu CR, Tschernyavsky SJ, Decuseara R et al. Prognostic impact of p53 status, TLS-CHOP fusion transcript structure and histologic grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin. Cancer Res.7(22), 3977–3987 (2001).
   PubMed Web of Science ®Google Scholar
• Huang HY, Antonescu CR. Molecular variability of TLS-CHOP structure shows no significant impact on the level of adipogenesis: a comparative ultrastructural and RT0-PCR analysis of 14 cases of myxoid/round cell liposarcomas. Ultrastruct. Pathol.27(4), 217–226 (2003).
   PubMedGoogle Scholar
• Antonescu CR. The role of genetic testing in soft tissue sarcoma. Histopathology48(1), 13–21 (2006).
   PubMed Web of Science ®Google Scholar
• Panagopoulos I, Mertens F, Isakson M, Mandahl N. Expression of DOL54 is not restricted to myxoid liposarcomas with the FUS-DDIT3 chimera but is found in various sarcomas. Oncol. Rep.12(1), 107–110 (2004).
   PubMed Web of Science ®Google Scholar
• Perez-Mancera PA, Sanchez-Garcia I. Understanding mesenchymal cancer: the liposarcoma-associated FUS-DDIT3 fusion gene as a model. Semin. Cancer Biol.15(3), 206–214 (2005).
   PubMedGoogle Scholar
• Goransson M, Elias E, Stahlberg A et al. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP β-mediated interleukin-6 expression. Int. J. Cancer115(4), 556–560 (2005).
   PubMed Web of Science ®Google Scholar
• Engstrom K, Willen H, Kabjorn-Gustafsson C et al. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. Am. J. Pathol.168(5), 1642–1653 (2006).
   PubMed Web of Science ®Google Scholar
• Matsui Y, Ueda T, Kubo T et al. A novel type of EWS-CHOP fusion gene in myxoid liposarcoma. Biochem. Biophys. Res. Commun.348(2), 437440 (2006).
   Google Scholar
• Riggi N, Cironi L, Provero P et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res.66(14), 7016–7023 (2006).
   PubMed Web of Science ®Google Scholar
• Costa A, Daidone MG, Daprai L et al. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res.66(17), 8918–8924 (2006).
   PubMed Web of Science ®Google Scholar
• Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N. Engl. J. Med.353(7), 701–711 (2005).
   PubMed Web of Science ®Google Scholar
• van de Rijn M, Fletcher JA. Genetics of soft tissue tumors. Annu. Rev. Pathol. Mech. Dis.1, 435–466 (2006).
   PubMed Web of Science ®Google Scholar
• Nielsen TO. Microarray analysis of sarcomas. Adv. Anat. Pathol.13(4), 166–173 (2006).
   PubMedGoogle Scholar
• Lazar A, Abruzzo LV, Pollock RE et al. Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas. Arch. Pathol. Lab. Med.130(6), 1199–1207 (2006).
   PubMed Web of Science ®Google Scholar
• Torchia EC, Jaishankar S, Baker SJ. Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res.63(13), 3464–3468 (2003).
   PubMed Web of Science ®Google Scholar
• Staege MS, Hutter C, Neumann I et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res.64(22), 8213–8221 (2004).
   PubMed Web of Science ®Google Scholar
• Carvajal R, Meyers P. Ewing’s sarcoma and primitive neuroectodermal family of tumors. Hematol. Oncol. Clin. North Am.19(3), 501–525 (2005).
   PubMed Web of Science ®Google Scholar
• Matsunobu T, Tanaka K, Nakamura T et al. The possible role of EWS-FLi1 in evasion of senescence in Ewing family tumors. Cancer Res.66(2), 803–811 (2006).
   PubMed Web of Science ®Google Scholar
• Saito T, Nagai M, Ladanyi M. SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by Snail and Slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. Cancer Res.66(14), 6919–6927 (2006).
   PubMedGoogle Scholar
• de Bruijn DRH, Allander SV, Anke HA et al. The synovial sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer Res.66(19), 9474–9482 (2006).
   PubMed Web of Science ®Google Scholar
• Moreno-Bueno G, Cubillo E, Sarrió D et al. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug and E47 factors in epithelial-mesenchymal transition. Cancer Res.66(19), 9543–9556 (2006).
   PubMed Web of Science ®Google Scholar
• de Torres C, Cardesa TM, Rodriguez-Perales S et al. Epithelioid sarcoma with SYT-SSX1 fusion gene expression: molecular and cytogenetic analysis. Cancer Genet. Cytogenet.162(1), 50–56 (2005).
   PubMedGoogle Scholar
• Kato H, Hatori M, Kokubun S et al. Ca 125 expression in epithelioid sarcoma. Jpn. J. Clin. Oncol.34(3), 149–154 (2004).
   PubMed Web of Science ®Google Scholar
• Kagami S, Saeki H, Idezuki T et al. Epithelioid sarcoma associated with lung adenocarcinoma. J. Dermatol.32(11), 904–908 (2005).
   PubMedGoogle Scholar
• Fisher C. Epithelioid sarcoma of Enzinger. Adv. Anat. Pathol.13(3), 114–121 (2006).
   PubMed Web of Science ®Google Scholar
• Pretto D, Barco R, Rivera J et al. The synovial sarcoma translocation protein SYT-SSX2 recruits β-catenin to the nucleus and associates with it in an active complex. Oncogene25(26), 3661–3669 (2006).
   PubMed Web of Science ®Google Scholar
• Kawaguchi S, Goto Y, Ihara K et al. Survival analysis with p27 expression and apoptosis appears to estimate the prognosis of patients with synovial sarcoma more accurately. Cancer94(10), 2712–2718 (2002).
   PubMedGoogle Scholar
• Olsen RJ, Lydiatt WM, Koepsell SA et al. C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck. Head Neck27(10), 883–92 (2005).
   PubMed Web of Science ®Google Scholar
• Sápi Z, Pápai Zs, Hruska A et al. Her-2 oncogene amplification, chromosome 17 and DNA ploidy status in synovial sarcoma. Pathol. Oncol. Res.11(3), 133–138 (2005).
   PubMedGoogle Scholar
• Sun Y, Gao D, Liu Y et al. IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene25(7), 1042–1052 (2006).
   PubMed Web of Science ®Google Scholar
• Lopez-Guerrero JA, Navarro S, Noguera R et al. Mutational analysis of the c-Kit and PDGFRα in a series of molecularly well-characterized synovial sarcomas. Diagn. Mol. Pathol.14(3), 134–139 (2005).
   PubMedGoogle Scholar
• Nagayama S, Fukukawa C, Katagiri T et al. Therapeutic potential of antibodies against FZD 10, a cell surface protein, for synovial sarcoma. Oncogene24(41), 6201–6212 (2005).
   PubMed Web of Science ®Google Scholar
• Nagayama S, Iiizumi M, Katagiri T et al. Identification of PDZK4, a novel human gene with PDZ domains, that is upregulated in synovial sarcoma. Oncogene23(32), 5551–5557 (2004).
   PubMedGoogle Scholar
• Kazanskaya O, Glinka A, Niehrs C. The role of Xenopus dickkopf1 in prechordial plate specification and neural pattering. Development127(22), 4981–4992 (2000).
   PubMedGoogle Scholar
• Shibata M, Ono H, Hikasa H et al. Xenopus crescent encoding a Frizzled-like domain is expressed in the Spemann organizer and pronephros. Mech. Dev.96(2), 243–246 (2000).
   PubMed Web of Science ®Google Scholar
• Guder C, Pinho S, Nacak TG et al. An ancient Wnt-Dickkopf antagonism in Hydra. Development133(5), 901–911 (2006).
   PubMed Web of Science ®Google Scholar
• Kuphal S, Lodermeyer S, Bataille F et al. Expression of Dickkopf genes is strongly reduced in malignant melanoma. Oncogene25(36), 5027–5036 (2006).
   PubMed Web of Science ®Google Scholar
• Tulac S, Overgaard MT, Hamilton AE et al. Dickkopf-1, an inhibitor of WNT signaling, is regulated by progesterone in human endometrial stromal cells. J. Clin. Endocrinol. Metab.91(4), 1453–1461 (2006).
   PubMedGoogle Scholar
• Iwasaki H, Isayama T, Ohjimi Y. et al. Malignant fibrous histiocytoma, a tumor of facultative histiocytes showing mesenchymal differentiation in cultured cell lines. Cancer69(2), 437–447 (1992).
   PubMedGoogle Scholar
• Kanzaki T, Kitajima S, Suzumoei K. Biological behavior of cloned cells of human malignant fibrous histiocytoma in vivo and in vitro. Cancer Res.51(8), 2133–2137 (1991).
   PubMedGoogle Scholar
• Gazziola C, Cordani N, Wasserman B et al. Malignant fibrous histiocytoma: a proposed cellular origin and identification of its characterizing gene transcripts. Int. J. Oncol.23(2), 343–351 (2003).
   PubMedGoogle Scholar
• Baird K, Davis S, Antonescu CR et al. Gene expression profiling of human sarcomas: insight into sarcoma biology. Cancer Res.65(20), 9226–9235 (2005).
   PubMed Web of Science ®Google Scholar
• Sorensen PH, Lynch JC, Qualman SJ et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children’s oncology group. J. Clin. Oncol.20(11), 2672–2679 (2002).
   PubMed Web of Science ®Google Scholar
• Xia SJ, Barr FG. Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein. Oncogene23(41), 6864–6871 (2004).
   PubMed Web of Science ®Google Scholar
• Davicioni E, Finckenstein FG, Shahbazian V et al. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcoma. Cancer Res.66(14), 6936–6946 (2006).
   PubMed Web of Science ®Google Scholar
• Bois PR, Izeradjene K, Houghton PJ et al. FOXOI1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J. Cell Biol.170(6), 903–912 (2005).
   PubMedGoogle Scholar
• Kawaguchi K-I, Oda Y, Saito T et al. Genetic and epigenetic alterations of the PTEN gene in soft tissue sarcomas. Hum. Pathol.36(4), 357–363 (2005).
   PubMedGoogle Scholar
• Pan X, Song Z, Zhai L et al. Chromatin-remodeling factor INI1/hSNF5/BAF47 is involved in activation of the colony stimulating factor 1 promoter. Mol. Cells20(2), 183–188 (2005).
   PubMedGoogle Scholar
• DeCristofaro MF, Betz BK, Wang W, Weissman BE. Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms’ tumors. Oncogene18(52), 7559–7565 (1999).
   PubMed Web of Science ®Google Scholar
• Pan X, Zhai L, Sun R et al. INI1/hSNF5/BAF47 represses c-fos transcription via a histone deacetylase-dependent manner. Biochem. Biophys. Res. Commun.337(4), 1052–1058 (2005).
   PubMedGoogle Scholar
• Cui K, Tailor P, Liu H et al. The chromatin-remodelling BAF complex mediates cellular antiviral activities by promoter priming. Mol. Cell Biol.24(10), 4476–4486 (2004).
   PubMed Web of Science ®Google Scholar
• Mercer SE, Ewton DZ, Shah S et al. Mirk/Dyrk1b mediates cell survival in rhabdomyosarcoma. Cancer Res.66(10), 5143–5150 (2006).
   PubMedGoogle Scholar
• Goldstein M, Meler I, Issakov J, Orr-Urtreger A. Novel genes implicated in embryonal, alveolar and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors. Neoplasia8(5), 332–343 (2006).
   PubMed Web of Science ®Google Scholar
• Schmidt D, Mackay B, Sinkovics JG. Retroperitoneal tumor with vertebral metastasis. Ultrastruct. Pathol.2(4), 383–388 (1982).
   Google Scholar
• Machinami R, Kikuchi F. Adenosine triphosphatase activity of crystalline inclusions in alveolar soft part sarcoma. An ultrahistochemical study of a case.Pathol. Res. Pract.181(3), 357–364 (1986).
   PubMedGoogle Scholar
• Logrono R, Wojtowycz MM, Wunderlich DW et al. Fine needle aspiration cytology and core biopsy in the diagnosis of alveolar soft part sarcoma presenting with lung metastases. A case report. Acta Cytol.43(3), 464–470 (1999).
   PubMedGoogle Scholar
• Ladanyi M, Lui MY, Antonescu CR et al. The der(17)t(X;17)(p11:q25) of human alveolar soft part sarcoma fuses the TFR3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene20(1), 48–57 (2001).
   PubMed Web of Science ®Google Scholar
• Uppal S, Aviv H, Patterson F et al. Alveolar soft part sarcoma – reciprocal translocation between chromosome 17q25 and Xp11. Report of a case with metastases at presentation and review of the literature. Acta Orthop. Belg.69(2), 182–187 (2003).
   PubMedGoogle Scholar
• Pang LJ, Li F, Chang B et al. Detection of ASPL-TEF3 fusion gene by reverse transcriptase polymerase chain reaction in paraffin-embedded tumor tissues of alveolar soft part sarcoma. Zhonghua Bing Li Xue Za Zhi33(6), 508–512 (2004).
   PubMedGoogle Scholar
• Roma AA, Yang B, Senior ME, Goldblum JR. TFE3 immunoreactivity in alveolar soft part sarcoma of the uterine cervix: case report. Int. J. Gynecol. Pathol.24(2), 131–135 (2005).
   PubMed Web of Science ®Google Scholar
• Huang HY, Lui MY, Ladanyi M. Nonrandom cell-cycle timing of a somatic chromosomal translocation: the t(X;17) of alveolar soft-part sarcoma occurs in G2. Genes Chromosomes Cancer44(2), 170–176 (2005).
   PubMedGoogle Scholar
• Koch MB, Shih IM, Weiss SW, Folpe AL. Microphthalmia transcription factor and melanoma cell adhesion molecule expression distinguish desmoplastic/spindle cell melanoma from morphologic mimics. Am. J. Surg. Pathol.25(1), 58–64 (2001).
   PubMed Web of Science ®Google Scholar
• Granter SR, Weilbaecher KN, Quigley C et al. Clear cell sarcoma show immunoreactivity for microphthalmia transcription factor: further evidence for melanocyte differentiation. Mod. Pathol.14(1), 6–9 (2001).
   PubMedGoogle Scholar
• Panagopoulos I, Mertens F, Debiec-Rychter M et al. Molecular genetic characterization of the EWS/ATF1 fusion gene in clear cell sarcoma of tendons and aponeuroses. Int. J. Cancer99(4), 560–567 (2002).
   PubMedGoogle Scholar
• Davis IJ, Kim JJ, Ozsolak F et al. Oncogenic MITF dysregulation in clear cell sarcoma: defining the MIT family of human cancers. Cancer Cell9(6), 473–484 (2006).
   PubMed Web of Science ®Google Scholar
• Willmore-Payne C, Holden JA, Hirschowitz S, Layfield LJ. BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum. Pathol.37(5), 520–527 (2006).
   PubMed Web of Science ®Google Scholar
• Coindre J-M, Hostein I, Terrier P et al. Diagnosis of clear cell sarcoma by real-time reverse transcriptase-polymerase chain reaction analysis of paraffin embedded tissues. Cancer107(5), 1055–1064 (2006).
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Nafa K, Segal NH et al. EWS-CREB1: a recurrent variant fusion in clear cell sarcoma-association with gastrointestinal location and absence of melanocytic differentiation. Clin. Cancer Res.12(18), 5356–5362 (2006).
   PubMed Web of Science ®Google Scholar
• Barr GF, Zhang PJ. The impact of genetics on sarcoma diagnosis: an evolving science. Clin. Cancer Res.12(18), 5256–5257 (2006).
   PubMedGoogle Scholar
• Llombart B, Sanmartin O, Lopez-Guerrero JA et al. Analysis of the COL1A1-PDGFB fusion gene of dermatofibrosarcoma protuberans with a fibrosarcoma component. Actas Dermosifiliogr.97(5), 337–341 (2006).
   PubMedGoogle Scholar
• Abbott JJ, Erickson-Johnson M, Wang X et al. Gains of COL1A1-PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Mod. Pathol.19(11), 1512–1518 (2006).
   PubMed Web of Science ®Google Scholar
• Kutzner H. Expression of the human progenitor cell antigen CD34 (HPCA-1) distinguishes dermatofibrosarcoma protuberans from fibrous histiocytoma in formalin-fixed, paraffin-embeded tissue. J Am. Acad. Dermatol.28(4). 613–617 (1993).
   PubMed Web of Science ®Google Scholar
• Hanly AJ, Jorda M, Elgart GW et al. High proliferative activity excludes dermatofibrosarcoma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors. Arch. Pathol. Lab. Med.130(6), 831–834 (2006).
   PubMedGoogle Scholar
• Sturt NJ, Clark SK. Current ideas in desmoid tumors. Fam. Cancer5(3), 275–285 (2006).
   PubMedGoogle Scholar
• Ferenc T, Sygut J, Kopczynski J et al. Aggressive fibromatosis (desmoid tumors): definition, occurrence, pathology, diagnostic problems, clinical behavior, genetic background. Pol. J. Pathol.57(1), 5–15 (2006).
   PubMedGoogle Scholar
• Cheon SS, Cheah AY, Turley S et al. β-catenin stabilization dysregulates mesenchymal cell motility and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc. Natl. Acad. Sci. USA99(10), 6973–6978 (2002).
   PubMed Web of Science ®Google Scholar
• Tejpatr S, Michilis G, Denys H et al. Analysis of Wnt/β-catenin signaling in desmoid tumors. Acta Gastroenterol. Belg.68(1), 5–9 (2005).
   PubMedGoogle Scholar
• Ng TL, Gown AM, Barry TS et al. Nuclear β-catenin in mesenchymal tumors. Mod. Pathol.18(1), 68–74 (2005).
   PubMed Web of Science ®Google Scholar
• Amini Nik S, Hohenstein P, Jadidizadeh A et al. Upregulation of Wilms’ tumor gene 1 (WT1) in desmoid tumors. Int. J. Cancer114(2), 202–208 (2005).
   PubMedGoogle Scholar
• Koontz JI, Soreng AL, Nucci M et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc. Natl. Acad. Sci. USA98(11), 6348–6353 (2001).
   PubMed Web of Science ®Google Scholar
• Micci F, Walter CU, Teixeira MR et al. Cytogenetic and molecular genetic analyses of endometrial stromal sarcoma: nonrandom involvement of chromosome arms 6p and 7p and confirmation of JAZF1/JJAZ1 gene fusion in t(7;17). Cancer Genet. Cytogenet.144(2), 119–124 (2003).
   PubMedGoogle Scholar
• Micci F, Panagopoulos I, Bjerkehagen B, Heim S. Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC/PHF1 in endometrial stromal sarcoma. Cancer Res.66(1), 107–112 (2006).
   PubMed Web of Science ®Google Scholar
• Adams SF, Hickson JA, Hutto JY et al. PDGFR-α as a potential therapeutic target in uterine sarcomas. Gynecol. Oncol. (2006).
   Google Scholar
• Connor JP. Aggressive carcinosarcoma of the uterine cervix associated with high levels of granulocyte colony stimulating factor: case report and laboratory correlates. Gynecol. Oncol.103(1), 349–353 (2006).
   PubMedGoogle Scholar
• Raspollini MR, Susini T, Amunni G et al. Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas; a marker for potential molecularly targeted treatment. Int. J. Gynecol. Cancer16(1), 416–422 (2006).
   PubMed Web of Science ®Google Scholar
• Liang S, Stone G, Chalas E et al. A high-grade leiomyosarcoma with chorionic gonadotropin production. Int. J. Gynecol. Pathol.25(3), 257–261 (2006).
   PubMedGoogle Scholar
• Fuchs B, Spinner RJ, Rock MG. Malignant peripheral nerve sheath tumors: an update. J. Surg. Orthop. Adv.14(4), 168–174 (2005).
   PubMedGoogle Scholar
• Upadhyaya M, Spurlock G, Majounie E et al. The heterogeneous nature of germline mutations in NF1 patients with malignant nerve sheath tumours MNSTs). Hum. Mutat.27(7), 716 (2006).
   PubMed Web of Science ®Google Scholar
• Sabah M, Cummins R, Leader M, Kay E. Loss of p16 (INK4A) expression is associated with allelic imbalance/loss of heterozygosity of chromosome 9p21 in microdissected malignant peripheral nerve sheath tumors. Appl. Immunohistochem. Mol. Morphol.14(1), 97–102 (2006).
   PubMedGoogle Scholar
• Lee PR, Cohen JE, Fields RD. Immune system evasion by peripheral nerve sheath tumors. Neurosci. Lett.397(1–2), 126–129 (2006).
   PubMedGoogle Scholar
• Storlazzi CT, Brekke HR, Mandahl N et al. Identification of a novel amplicon at distal 17q containing the BIRC5/Survivin gene in malignant peripheral nerve sheath tumours. J. Pathol.209(4), 492–500 (2006).
   PubMed Web of Science ®Google Scholar
• Sinkovics JG, Papadopoulos N, Plager C et al. Neurofibromatosis of von Recklinghausen: survival determinants of 27 patients with sarcomatous transformation. Proceedings 16th Annual Meeting American Society Clinical Oncology, San Diego, CA, USA. 21, 480 (1980) (Abstract C635).
   Google Scholar
• Anghileri M, Miceli R, Fiore M et al. Malignant peripheral nerve sheath tumors. Cancer107, 1065–1074 (2006).
   PubMed Web of Science ®Google Scholar
• Gordon WL, Haber DA. The EWS-WT1 gene fusion in desmoplastic small round cell tumor. Semin. Cancer Biol.15(3), 197–205 (2005).
   PubMedGoogle Scholar
• Werner H, Idelman G, Rubinstein M et al. A novel EWS-WT1 gene fusion product in desmoplastic small round cell tumor is a potent transactivator of the insulin-like growth factor-1 receptor (IGF-IR) gene. Cancer Lett . (2006).
   PubMedGoogle Scholar
• Lee SB, Kolquist KA, Nichols K et al. The EWS-WT1 translocation product induces PDGF-α in desmoplastic small round-cell tumour. Nat. Genet.17(3), 309–313 (1997).
   PubMed Web of Science ®Google Scholar
• Froberg K, Brown RE, Gaylord H, Manivel C. Intra-abdominal desmoplastic small round cell tumor: immunohistochemical evidence for up-regulation of autocrine and paracrine growth factors. Ann. Clin. Lab. Sci.28(6), 386–396 (1998).
   PubMedGoogle Scholar
• Zhang PJ, Goldblum JR, Pawel BR et al. PDGF-A, PDGR-Rβ, TGFβ3 and bone morphogenic protein-4 in desmoplastic small round cell tumors with EWS-WT1 gene fusion product and their role in stromal desmoplasia: an imunohistochemical study. Mod. Pathol.18(3), 382–387 (2005).
   PubMed Web of Science ®Google Scholar
• Fine RL, Shah SS, Moulton TA et al. Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy. Cancer Chemother. Pharmacol. (2006).
   PubMedGoogle Scholar
• Yang SF, Wang SL, Chai CY et al. Intra-abdominal desmoplastic small round cell tumor with elevated serum Ca 125: a case report. Kaoshiung J. Med. Sci.19(10), 531–536 (2003).
   Google Scholar
• Hassan I, Shyyan R, Donohue JH et al. Intraabdominal desmoplastic small round cell tumors. Cancer104(6), 1264–1270 (2005).
   PubMedGoogle Scholar
• Ueda T, Oji Y, Naka N et al. Overexpression of the Wilms’ tumor gene WT1 in human bone and soft-tissue sarcomas. Cancer Sci.94(3), 271–276 (2003).
   PubMedGoogle Scholar
• Sotobori T, Ueda T, Oji Y et al. Prognostic significance of Wilms’ tumor gene (WT1) mRNA expression in soft tissue sarcoma. Cancer106(19), 2233–2240 (2006).
   PubMed Web of Science ®Google Scholar
• Carbone M, Bedrossian CW. The pathogenesis of mesothelioma. Semin. Diagn. Pathol.23(1), 56–60 (2006).
   PubMed Web of Science ®Google Scholar
• Pershouse MA, Heivly S, Girtsman T. The role of SV40 in malignant mesothelioma and other human malignancies. Inhal. Toxicol.18(12), 995–1000 (2006).
   PubMed Web of Science ®Google Scholar
• Spugnini EP, Bosari S, Citro G et al. Human malignant mesothelioma: molecular mechanisms of pathogenesis and progression. Int. J. Biochem. Cell Biol.38(12), 2000–2004 (2006).
   PubMedGoogle Scholar
• Davidson B, Zhang Z, Kleinberg L et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin. Cancer Res.12(20), 5944–5950 (2006).
   PubMed Web of Science ®Google Scholar
• Ordóñez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum. Pathol.38(1), 1–16 (2007).
   PubMed Web of Science ®Google Scholar
• Whitson BA, Jacobson BA, Frizelle S et al. Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Ann. Thorac. Surg.9, 96–101 (2006).
   Google Scholar
• Nishimura M, Itoh K, Ito K et al. Autocrine growth by granulocyte colony-stimulating factor in malignant mesothelioma. Ann. Thorac. Surg.82(5), 1904–1906 (2006).
   PubMedGoogle Scholar
• Sinkovics JG. New biological therapeutics: competitors or collaborators of viral therapy for human cancers. In: Viral Therapy of Human Cancers. Sinkovics JG, Horvath JC (Authors & Editors). Marcel Dekker, New York, USA, 266 268, 338–339 (2005).
   Google Scholar
• Sinkovics JG. Chondrosarcoma cell differentiation. Pathol. Oncol. Res.10(3), 174–187 (2004).
   PubMedGoogle Scholar
• Sinkovics JG. A reappraisal of cytotoxic lymphocytes in human tumor immunology. In: Cancer Biology and Therapeutics. First H. Lee Moffitt International Symposium. Cory JG, Szentivanyi A (Ed). Plenum Press, New York, NY, USA & London, UK. 225–253 (1987).
   Google Scholar
• Sinkovics JG, Horvath JC. Human natural killer cells: a comprehensive review. Int. J. Oncol.27(1), 5–47 (2005).
   PubMed Web of Science ®Google Scholar
• Vánky F, Stjernswärd J, Nilsonne U. Cellular immunity to human sarcoma. J. Natl. Cancer Inst.46, 1145–1151 (1971).
   PubMedGoogle Scholar
• Klein E, Vánky F. Natural and activated cytotoxic lymphocytes which act on autologous and allogeneic tumor cells. Cancer Immunol. Immunother.11(3), 183 (1981).
   Google Scholar
• Sinkovics JG, Cabiness JR, Shullenberger CC. In vitro cytotoxicity of lymphocytes to human sarcoma cells. Bibliotheca Haematologica39, 846–851 (1973).
   PubMedGoogle Scholar
• Lee SY, Obata Y, Yoshida M et al. Immunomic analysis of human sarcoma. Proc. Natl. Acad. Sci. USA100(5), 2651–2656 (2003).
   PubMed Web of Science ®Google Scholar
• Segal NH, Blachere NE, Guevara-Patino JA et al. Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. Cancer Immun.5, 2 (2005).
   PubMedGoogle Scholar
• Zendman AJ, Van Kraatz AA, Welde UH et al. The Xage family of cancer/testis-associated genes: alignement and expression profile in normal tissues, melanoma lesions and Ewing’s sarcoma. Int. J. Cancer99(3), 361–369 (2002).
   PubMed Web of Science ®Google Scholar
• Matsuzaki A, Suminoe A, Hattori H et al. Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma. J. Pediatr. Hematol. Oncol.24(3), 220–223 (2002).
   PubMed Web of Science ®Google Scholar
• Ackermann B, Troger A, Glouchkova L et al. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant tumors and a poor prognosis. Klin. Pädiatr.216(3), 176–182 (2004).
   PubMedGoogle Scholar
• Pritchard-Jones K, SpendloveI, Wilton C et al. Immune responses to the 105AD7 human anti-idiotype vaccine after intensive chemotherapy, for osteosarcoma. Br. J. Cancer92(8), 1358–1365 (2005).
   PubMed Web of Science ®Google Scholar
• De Hooge ASK, Annals NE, Ten Dam M et al. PRAME: a target antigen for immunotherapy in Ewing’s sarcoma. Proceedings 96th Annual Meeting American Association Cancer Research. Anaheim, CA, USA. 46, 1112 (2005) (Abstract 4715).
   Google Scholar
• Morrison DJ, English MA, Licht JD. WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak. Cancer Res.65(18), 8174–8182 (2005).
   PubMed Web of Science ®Google Scholar
• Ito K, Oji Y, Tatsumi N et al. Antiapoptotic function of 17AA+WT1 (Wilms’ tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene25(30), 4217–4229 (2006).
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Kawakami M et al. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr. Med. Chem.13(20), 2345–2352 (2006).
   PubMed Web of Science ®Google Scholar
• Morita S, Oka Y, Tsuboi A et al. A Phase I/II trial of a WT1 (Wilms’ tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn. J. Clin. Oncol.36(4), 231–236 (2006).
   PubMed Web of Science ®Google Scholar
• Tsuboi A, Oka Y, Ogawa H et al. Cytotoxic T-lymphocyte responses elicited to Wilms’ tumor gene WT1 product by DNA vaccination. J. Clin. Immunol.20(3), 195–202 (2000).
   PubMed Web of Science ®Google Scholar
• Gaiger A, Carter L, Greinix H et al. WT1-specific serum antibodies in patients with leukemia. Clin. Cancer Res.7(3), S761–S765 (2001).
   PubMedGoogle Scholar
• Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl. Acad. Sci. USA101(38), 13885–13890 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia17(7), 1301–1312 (2003).
   PubMed Web of Science ®Google Scholar
• Mailander V, Scheibenbogen C, Thiel E et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in absence of hematological or renal toxicity. Leukemia18(1), 165–166 (2004).
   PubMed Web of Science ®Google Scholar
• Rauscher FJ 3rd, Benjamin LE, Fredericks WJ, Morris JF. Novel oncogenic mutations in the WT1 Wilms’ tumor suppressor gene: a t(11;22) fuses the Ewing’s sarcoma gene, EWDS1, to WT1 in desmoplastic small round cell tumor. Cold Spring Harb. Quant. Biol.59, 137–146 (1994).
   PubMedGoogle Scholar
• Vonderheide RH anderson K, Hahn WC et al. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin. Cancer Res.7(11), 3343–3348 (2001).
   PubMed Web of Science ®Google Scholar
• Anderson MH, Soerensen RB, Becker JC, Thor Straten P. HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer. J. Transl. Med. (2006) (Epub ahead of print).
   Google Scholar
• Worley BS, van den Broeke LT, Goletz TJ et al. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res.61(18), 6868–6875 (2001).
   PubMed Web of Science ®Google Scholar
• van den Broeke LT, Pendleton CD, Mackall C et al. Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. Cancer Res.66(3), 1818–1823 (2006).
   PubMed Web of Science ®Google Scholar
• Tsuji T, Yasukawa M, Matsuzaki J et al. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor-peptide specific T-cell receptor genes. Blood106(2), 470–476 (2005).
   PubMed Web of Science ®Google Scholar
• Barath S, Aleksza M, Keresztes K et al. Immunoregulatory T cells in the peripheral blood of patients with Hodgkin’s lymphoma. Acta Haematol.116(3), 181–185 (2006).
   PubMedGoogle Scholar
• Banham AH, Powrie FM, Suri-Payer E. FOXP3+ regulatory T cells: current controversies and future perspectives. Eur. J. Immunol.36(11), 2832–2836 (2006).
   PubMed Web of Science ®Google Scholar
• Ralainirina N, Poli A, Michel T et al. Control of natural killer (NK) cell functions by CD4+CD25+ regulatory T cells. J. Leukoc. Biol. (2006) (Submitted).
   PubMedGoogle Scholar
• Lizee G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin. Cancer Res.12(16), 4794–4803 (2006).
   PubMed Web of Science ®Google Scholar
• Zom E, Ritz J. Studying human regulatory T cells in vivo. Clin. Cancer Res.12(18), 5265–5267 (2006).
   PubMedGoogle Scholar
• Shevach EM. Fatal attraction: tumors beckon regulatory T cells. Nat. Med.10(9), 900–901 (2004).
   PubMed Web of Science ®Google Scholar
• Fruehauf S, Seeger T, Maier P et al. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp. Hematol.34(8), 1052–1059 (2006).
   PubMedGoogle Scholar
• Guleng B, Tateishi K, Ohta M et al. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res.65(13), 5864–5871 (2005).
   PubMed Web of Science ®Google Scholar
• Pasternak A, Marino D, Vicarioi PP et al. Novel, orally bioavailable γ-aminoamide CC chemokine receptor 2 (CCR2) antagonists. J. Med. Chem.49(16), 4801–4804 (2006).
   PubMed Web of Science ®Google Scholar
• Hatse S, Princen K, DE Clercq E et al. AMD3465, a monomacrocyclic CXC4 antagonist and potent HIV entry inhibitor. Biochem. Pharmacol.70(5), 752–761 (2005).
   PubMed Web of Science ®Google Scholar
• von Luettichau I, Nathrath M. Mononuclear infiltrates in osteosarcoma and chemokine receptor expression. Clin. Cancer Res.12(17), 5253 (2006).
   PubMedGoogle Scholar
• Laverdière C, Gorlick R. CXCR4 expression in osteosarcoma cell lines and tumor samples: evidence for expression by tumor cells. Clin. Cancer Res.12(17), 5254 (2006).
   Google Scholar
• Valenti R, Huber V, Filipazzi P et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-β-mediated suppressive activity on T lymphocytes. Cancer Res.66(18), 9290–9298 (2006).
   PubMed Web of Science ®Google Scholar
• Frey AB. Myeloid suppressor cells regulate the adaptive immune response to cancer. J. Clin. Invest.116(10) 2587–2590 (2006).
   PubMed Web of Science ®Google Scholar
• Tsukahara T, Kawaguchi S, Ida K et al. HLA-restricted specific tumor cytolysis by autologous T-lymphocytes infiltrating metastatic bone malignant fibrous histiocytoma of lymph node. Orthop. Res.24(1) 94–101 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson P. Liposomal maramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Future Oncol.2(3), 333–343 (2006).
   PubMedGoogle Scholar
• Nardin A, Lefebvre ML, Labroquere K et al. Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr. Cancer Drug Targets6(2) 123–133 (2006).
   PubMed Web of Science ®Google Scholar
• Nakashima Y, Deie M, Yanada S et al. Magnetically labeled human natural killer cells, accumulated in vitro by an external magnetic force, are effective against HOS osteosarcoma cells. Int. J. Oncol.27(4), 965–971 (2005).
   PubMedGoogle Scholar
• Oikawa K, Ishida T, Imamura T et al. Generation of the novel monoclonal antibody against TLS/EWS-CHOP chimeric oncoprotein that is applicable to one of the most sensitive assays for myxoid and round cell liposarcomas. Am. J. Surg. Pathol.30(3), 351–356 (2006).
   PubMed Web of Science ®Google Scholar
• Modak S, Guo HF, Humm JL et al. Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9. Cancer Biother. Radiopharm.20(5), 534–546 (2005).
   PubMedGoogle Scholar
• D’Adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J. Clin. Oncol.23(28), 7135–7142 (2005).
   PubMed Web of Science ®Google Scholar
• Aryee DNT, Muelbacher K, Kovar H. Single-chain antibodies from a phage display library differentiate endogenous EWS from its oncogenic derivative EWS-FLI1. Proccedings 96th Annual Meeting American Association Cancer Research. Anaheim, CA, USA. 46, 880 (2005) (Abstract 3733).
   Google Scholar
• Sohn HW, Choi EY, Kim SH et al. Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing’s sarcoma cells. Am. J. Pathol.153(6), 1937–1945 (1998).
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Baldini N, Cerisano V et al. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res.60(18), 5134–5142 (2000).
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Perdichizzi S, Bernard G et al. Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing’s sarcoma. Eur. J. Cancer42(1), 91–96 (2006).
   PubMed Web of Science ®Google Scholar
• Li W, Bertino JR. Fas-mediated signaling enhances sensitivity of human soft tissue sarcoma cells to anticancer drugs by activation of p53 kinase. Mol. Cancer Ther.1(14), 1343–1348 (2002).
   PubMedGoogle Scholar
• Mitsiades N, Poulaki V, Kotoula V et al. Fas ligand is present in tumors of the Ewing’s sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am. J. Pathol.153(6), 1947–1956 (1998).
   PubMedGoogle Scholar
• Sinkovics JG. Malignant lymphoma arising from natural killer cells: report of the first case in 1970 and newer developments in the FasL→FasR system. Acta Microbiol. Immunol. Hungar.44(3), 295–307 (1997).
   PubMedGoogle Scholar
• Horvath JC, Horvath E, Sinkovics JG et al. Human melanoma cells (HMC) eliminate autologous host lymphocytes (LyFasR+) and escape apoptotic death by utilizing the FasL→FasR system as an autocrine growth loop (HMCFasL+ → Ly FasR+). Proceedings 89th Annual Meeting American Association Cancer Research. New Orleans, LA, USA. 38, 2371 (1998) (Abstract 584).
   Google Scholar
• Shinohara H, Yagita H, Ikawa Y, Oyaizu N. Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. Cancer Res.60, 1766–1772 (2000).
   PubMed Web of Science ®Google Scholar
• Tjandra SS, Yu C-Y, Goh I, Alman BA. Type 1 interferon promotes tumorigenesis in aggressive fibromatosis. Proceedings 97^th Annual Meeting American Association Cancer Research. Washington, DC, USA. 47, 911 (2006) (Abstract 3874).
   Google Scholar
• Sinkovics JG. Oncogenes and growth factors. CRC Crit. Rev. Immunol.8(4), 217–298 (1988).
   Google Scholar
• Manara MC, Serra M, Benini S et al. Effectiveness of type I interferons in the treatment of multidrug resistant osteosarcoma cells. Int. J. Oncol.24(2), 365–372 (2004).
   PubMed Web of Science ®Google Scholar
• Muller CR, Smeland S, Bauer HC et al. Interferon-α as the only adjuvant treatment in high grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol.44(5), 475–480 (2005).
   PubMed Web of Science ®Google Scholar
• Benjamin RS, Patel SR, Gutterman JU et al. Interferon α2b as anti-angiogenesis therapy of giant cell tumors of bone: implications for the study of newer angiogenesis-inhibitors. Proceedings 35th Annual Meeting American Society Clinical Oncology, USA.18, 548a (1999) (Abstract 2114).
   Google Scholar
• Gonzalez Vela JL, Lozano CE, Oyervides VMS et al. Therapy with α interferon for advanced and metastatic giant cell tumor of bone. Proceedings 41st Annual Meeting American Society Clinical Oncology. Orlando, FL, USA. J. Clin. Oncol.23(Suppl. 16) Part I, S835 (2005) (Abstract 9078).
   Google Scholar
• Choi BS, Sondel PM, Hank JA et al. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma and sarcoma. Cancer Immunol. Immunother.55(7), 761–774 (2006).
   Google Scholar
• Honorati MC, Neri S, Cattini L, Facchini A. IL-17 enhances susceptibility of U-2 OS osteosarcoma cells to NK cell lysis. Clin. Exp. Immunol.133(3), 344–349 (2003).
   PubMedGoogle Scholar
• Papachristou DJ, Goodman MA, Cieply K et al. Comparison of allelic losses in chondroblastoma and primary chondrosarcoma of bone and correlation with fluorescence in situ hybridization analysis. Hum. Pathol.37(7), 890–898 (2006).
   PubMedGoogle Scholar
• Wehrli BM, Huang W, De Crombrugghe B et al. Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors. Hum. Pathol.34(3), 263–269 (2003).
   PubMedGoogle Scholar
• Kalinski T, Krueger S, Sel S et al. ADAMTS1 is regulated by interleukin-1β, not hypoxia, in chondrosarcoma. Hum. Pathol. (2006) (Epub ahead of print).
   PubMedGoogle Scholar
• Pedeutour F, Maire G, Sirvent N; Groupe Francophone de Cytogenetique Oncologique. Bull. Cancer91(4), 317–323 (2004).
   PubMedGoogle Scholar
• Storlazzi CT, Mertens F, Nascimento A et al. Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma. Hum. Mol. Genet.12(18), 2349–2358 (2003).
   PubMedGoogle Scholar
• Mertens F, Fletcher CD, Antonescu C et al. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma and cloning of a novel FUS/CREB3L1 fusion gene. Lab.Invest.85(3), 408–415 (2005).
   PubMed Web of Science ®Google Scholar
• Panagopoulos I, Moller E, Dahlen A et al. Characterization of the native CREB3L2 transcription factor and the FUS/CREB3L2 chimera. Genes Chromosomes Cancer46(2), 181–191 (2007).
   PubMed Web of Science ®Google Scholar
• Prinz S, Amon A, Klein F. Isolation of COM1, a new gene required to complete meiotic double-strand break-induced recombination in Saccharomyces cerevisiae. Genetics146(3), 781–795 (1997).
   PubMed Web of Science ®Google Scholar
• Ishida M, Miyamoto M, Naitoh S et al. The SYT-SSX fusion protein down-regulates the cell proliferation regulator COM1 in t(X;18) synovial sarcoma. Mol. Cell Biol. (2006) (Submitted).
   PubMedGoogle Scholar
• Sun BC, Sun Y, Zhao XL et al. Expression and significance of E-cadherin and β-catenin in synovial sarcoma. Zhonghua Zhong Liu Za Zhi27(12), 727–730 (2005).
   PubMedGoogle Scholar
• Carey KA, Segal D, Klein R et al. Identification of novel genes expressed during rhabdomyosarcoma differentiation using cDNA microarrays. Pathol. Int.56(5), 246–255 (2006).
   PubMedGoogle Scholar
• Khan J, Simon R, Bittner M et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res.58(22), 5009–5913 (1998).
   PubMed Web of Science ®Google Scholar
• Engellau J, Bendahl PO, Persson A et al. Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern and immunostaining using whole-tumor sections and tissue microarrays. Hum. Pathol.36(9), 994–1002 (2005).
   PubMed Web of Science ®Google Scholar